Selected Articles from This Issue
Journal: Clinical Cancer Research (2023)

Highlights| March 14 2023 Selected Articles from This Issue Author & Article Information Online ISSN: 1557-3265 Print ISSN: 1078-0432 ©2023 American Association for Cancer Research2023American Association for Cancer Research Clin Cancer Res (2023) 29 (6): 987. https://doi.org/10.1158/1078-0432.CCR-29-6-HI Related Content A commentary has been published: Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality A commentary has been published: A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated Liposarcoma A commentary has been published: Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer View more A commentary has been published: A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study View less See also commentary Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict MortalityIncreased CD83 Expression on GVHD Effector Cells A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated LiposarcomaSitravatinib in Advanced Liposarcoma Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal CancerBCL-XL Inhibition Unleashes Apoptosis in EGFR-Inhibited CRC A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) StudyBRAF and EGFR Inhibition in BRAF V600E Colorectal Cancer and Other Cancers Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record March 14 2023 Citation Selected Articles from This Issue. Clin Cancer Res 15 March 2023; 29 (6): 987. https://doi.org/10.1158/1078-0432.CCR-29-6-HI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Tan and colleagues conducted a phase Ib/II dose-escalation/expansion trial investigating the safety/efficacy of the BRAF inhibitor vemurafenib and EGFR inhibitor erlotinib. Patients with BRAF V600E positive metastatic colorectal cancer (mCRC) and other cancers were enrolled. No dose-limiting toxicities were observed in escalation, with vemurafenib 960 mg/twice-daily with erlotinib 150 mg/daily selected as the recommended phase II dose. Overall response rates were 32% and 43%, respectively, with clinical benefit rates of 65% and 100%. Early ctDNA dynamics were predictive of treatment efficacy and serial ctDNA monitoring revealed distinct patterns of convergent genomic evolution associated with acquired treatment resistance, with frequent emergence of MAPK pathway alterations and MET amplification. These results indicate that the novel combination of vemurafenib and erlotinib is well tolerated, with promising activity in BRAF V600E CRC and other tumor types. These findings highlight that ctDNA analysis can reveal important insights into mechanisms of treatment resistance and provides an... You do not currently have access to this content.